Related Experiment Video
Updated: Feb 14, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
PXR polymorphisms have impact on the clinical efficacy of clopidogrel in patients undergoing percutaneous coronary
Yan Wu1, Hua Yu2, Hai-Qin Tang3
1Department of Pharmacy, Anhui Provincial Hospital, Hefei, China; Department of Pharmacy, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
Insights
Genetic variations in the pregnane X receptor (PXR) influence clopidogrel treatment effectiveness in patients undergoing percutaneous coronary intervention (PCI). Specific PXR polymorphisms are linked to major adverse cardiovascular events (MACE) after PCI.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Genetics
Background:
- Clopidogrel is a key antiplatelet medication for Coronary Heart Disease (CHD) patients post-percutaneous coronary intervention (PCI).
- Clopidogrel response variability (CRV) impacts clinical outcomes, with genetic factors playing a significant role.
- The pregnane X receptor (PXR, NR1I2) is implicated in drug metabolism and response.
Purpose of the Study:
- To investigate the association between PXR genetic polymorphisms and the clinical efficacy of clopidogrel in PCI patients.
- To determine if specific PXR gene variants influence the risk of thrombotic events or other adverse outcomes.
Main Methods:
- 384 patients undergoing PCI and treated with dual antiplatelet therapy (DAPT) were enrolled.
- Plasma clopidogrel carboxylic acid metabolites (CLPM) and platelet maximum aggregation rate (MAR) were measured.
- PXR genetic polymorphisms (rs3814057, rs3814058, rs6785049) and haplotypes were analyzed using Sequenom MassArray.
- Clinical outcomes, including major adverse cardiovascular events (MACE) and bleeding, were monitored for 12 months post-PCI.
Main Results:
- 153 patients experienced MACE, and 29 had bleeding events within 12 months.
- PXR polymorphisms rs3814057, rs3814058, and rs6785049 were significantly associated with MACE risk.
- Haplotype h1 (GCC) correlated with increased MACE risk, while haplotype h2 (AAT) was associated with a reduced risk.
Conclusions:
- Specific genotypes and haplotypes of PXR (rs3814057, rs3814058, rs6785049) significantly impact the occurrence of MACE in clopidogrel-treated patients post-PCI.
- These findings highlight the role of PXR genetics in clopidogrel pharmacogenomics and clinical outcomes.
- PXR genetic variations may serve as predictive markers for clopidogrel efficacy in PCI patients.
Backgrounds:
Clopidogrel is widely used in Coronary Heart Disease (CHD) patients undergoing percutaneous coronary intervention (PCI) to prevent thrombotic events. However, clopidogrel response variability (CRV) may affect the patients' clinical outcomes. The current data have shown that genetic factors play an important role in CRV. The aim of this research is to investigate the association of pregnane X receptor (PXR, also called NR1I2) genetic polymorphisms with the clinical efficacy of clopidogrel in patients undergoing PCI.
Methods:
A total of 384 patients undergoing PCI were recruited and treated with dual antiplatelet therapy (DAPT) for 12 months. The plasma concentration of clopidogrel carboxylic acid metabolites (CLPM) was measured by High Performance Liquid Chromatography (HPLC). The maximum aggregation rate (MAR) of platelet were measured by PL-11 analyzer. PXR genetic polymorphisms were determined by Sequenom MassArray system. The clinical outcomes were observed by readmission, outpatient and calling back interview within 12 months after PCI.
Results:
Among all 384 patients, a total of 153 patients were occurred with major adverse cardiovascular events (MACE), 29 patients were occurred with bleeding events, the other patients had a favorable prognosis. The polymprphisms of PXR rs3814057A > C [OR(95%CI): 0.71(0.527-0.957), P = 0.024], rs3814058T > C [OR (95%CI): 1.395(1.034-1.883), P = 0.029] and rs6785049 A > G [OR(95%CI): 0.724 (0.535-0.979), P = 0.036] were significantly associated with MACE. The haplotype h1 (GCC) was associated with a higher risk of MACE [OR (95%CI): 1.385 (1.028-1.866), P = 0.031]. Whereas, the haplotype h2 (AAT) was associated with a lower risk of MACE [OR (95%CI): 0.711(0.525-0.962), P = 0.027].
Conclusions:
The genotypes and haplotypes of PXR rs3814057, rs3814058 and rs6785049 have impact on the MACE in clopidogrel treated patients after PCI.
More Related Videos
07:59Therapy Interventions for Upper Limb Amputees Undergoing Selective Nerve Transfers
Published on: October 29, 2021
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
Related Concept Videos
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Coronary Artery Disease III: Clinical Manifestations
Nursing Interventions I: Taxonomy of Nursing Interventions
A nursing intervention is a treatment or action based on scientific concepts and knowledge from the nursing, behavioral, and physical sciences. Identifying and prioritizing nursing interventions based on the desired outcome...
Self-Efficacy
Nursing Interventions II: Selecting and Classifying the Nursing Interventions
Impact of Groups on Groups